Trials 'unable to bounce back' after COVID-19 chaos: report

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Despite some forward motion over the summer, studies for new drugs are still suffering.

Phesi, which offers trial solutions to life science companies, says its data “show clinical trial suspensions continue to rise as COVID-19 impact on development persists,” adding that costs are set to “spiral out of control” if companies fail to become data-driven by next year (a service it also offers).